Suggested remit: To appraise the clinical and cost effectiveness of efgartigimod with recombinant human hyaluronidase PH20 within its marketing authorisation for treating chronic inflammatory demyelinating polyneuropathy.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6409
Provisional Schedule
- Expected publication:
- 29 July 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email HST@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- argenx
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Guillain-Barré and Associated
- Inflammatory Neuropathies (GAIN)
- Professional groups
- Association of British Neurologists
- Royal College of Physicians
- Comparator companies
- Grifols UK (human immunoglobulin)
- Octapharma (human immunoglobulin)
- Takeda UK (human immunoglobulin)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 March 2026 | Committee meeting |
| 14 August 2025 | Invitation to participate |
| 28 January 2025 | Note - Note added to the project documents |
| 06 January 2025 (14:00) | Scoping workshop |
| 01 November 2024 - 29 November 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6409 |
| 01 November 2024 | In progress. Scoping commencing |
| 31 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual